“These results are exciting because depression is common in Parkinson’s but we weren’t sure about the best way to treat it. Older antidepressants are effective but have a lot of side effects.
The newer antidepressants have fewer side effects but we didn’t know if they’d be effective in people with Parkinson’s. We were also worried that they might worsen the motor problems that come with the disease,” said research author Irene H. Richard, MD, of the University of Rochester Medical Center in New York and a member of the American Academy of Neurology.
Parkinson's disease is a chronic neurologic disorder that worsens over time, leaving patients less able to direct or control their movements due to the loss of cells in various parts of the brain. In addition to the physical problems, Parkinson’s can also cause psychological symptoms. Almost one-half of people with Parkinson’s suffer from depression, and it is a major cause of disability.
The drugs tested were paroxetine, which is an antidepressant in the class called selective serotonin reuptake inhibitors (SSRIs), and venlafaxine extended release, which is in the serotonin and norepinephrine reuptake inhibitors (SNRIs) class.
The clinical trial lasted three months and involved 115 people in various stages of Parkinson’s disease who met the criteria for depression. About one-third of the participants received paroxetine, one-third received venlafaxine and one-third received a dummy pill. The dosage of the drug could be increased until the participant’s depression was effectively treated.On average, the people receiving paroxetine had a 13 point (59 percent) improvement and those receiving venlafaxine had an 11 point (52 percent) improvement in their scores on the Hamilton Rating Scale for Depression. People who received the dummy pill had a 6.8 point (32 percent) improvement. The results, as measured by three other depression rating scales, were similar. “The study suggests that, while there is a clear ‘placebo’ effect, there is a greater benefit from the antidepressant medications,” said Richard.
The study was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke and Johns Hopkins University School of Medicine. Wyeth Pharmaceuticals provided venlafaxine XR, while Glaxo-Smith Kline provided paroxetine.
The American Academy of Neurology, an association of 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease and multiple sclerosis.
For more information about the American Academy of Neurology, visit http://www.aan.com
Rachel L. Seroka | American Academy of Neurology
Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung
Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
22.08.2017 | Health and Medicine
22.08.2017 | Materials Sciences
22.08.2017 | Life Sciences